Quantum Biopharma

QNTM · CANADIAN

$2.24−$0.03 (−1.32%)TodayMarket closed · Oct 23, 7:49 PM ET

Prev close $2.27

Latest news

NewsOct 20, 6:45 AM ETAvi Kapoor
Top Wall Street Forecasters Revamp Thermo Fisher Scientific Expectations Ahead Of Q3 Earnings
Press releaseOct 8, 8:00 AM ETGlobe Newswire
World Renowned Law Firm Grant & Eisenhofer Appointed Lead Counsel In Newly Consolidated Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares
Press releaseOct 6, 6:00 AM ETGlobe Newswire
Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis
NewsOct 6, 5:48 AM ETVandana Singh
EXCLUSIVE: Thermo Fisher To Support Quantum Biopharma in Progressive Multiple Sclerosis Drug Trial
Press releaseSep 30, 8:00 AM ETGlobe Newswire
IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.
Press releaseSep 24, 8:00 AM ETGlobe Newswire
Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO
Press releaseSep 15, 8:00 AM ETGlobe Newswire
Quantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto
Press releaseSep 14, 8:30 AM ETGlobe Newswire
NetworkNewsAudio Announces Audio Press Release (APR) Discussing FDA Clearance for Trial of First-in-Class Treatment Creating ‘Rare Moment’ in MS Research
Press releaseSep 11, 8:30 AM ETGlobe Newswire
Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials
Press releaseSep 10, 8:30 AM ETGlobe Newswire
Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
Press releaseSep 9, 8:30 AM ETGlobe Newswire
Quantum BioPharma Ltd. NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment
Press releaseSep 8, 8:30 AM ETGlobe Newswire
A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach
NewsSep 2, 4:11 AM ET
Reported Earlier, Quantum BioPharma Plans To Leave Canadian Exchange While Keeping Nasdaq Listing
Press releaseSep 1, 7:00 PM ETGlobe Newswire
Quantum BioPharma Announces Plans to Voluntarily Delist its Class B Shares from the Canadian Securities Exchange
Press releaseAug 21, 7:00 PM ETGlobe Newswire
Quantum Biopharma Provides Corporate Update
NewsAug 17, 8:06 AM ET
12 Health Care Stocks Moving In Monday's Pre-Market Session
Press releaseAug 14, 7:00 AM ETGlobe Newswire
Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial
Press releaseAug 10, 7:00 AM ETGlobe Newswire
Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis:
NewsAug 10, 6:31 AM ETVandana Singh
EXCLUSIVE: Quantum BioPharma Achieves Major Milestone With FDA Clearance for Multiple Sclerosis Trial
Press releaseJul 30, 12:18 AM ETGlobe Newswire
Quantum BioPharma Announces Closing of Debt Settlement
Press releaseJul 20, 7:00 PM ETGlobe Newswire
Quantum BioPharma Announces Intention to Settle Debt
Press releaseJul 7, 7:00 PM ETGlobe Newswire
Quantum BioPharma Provides Corporate Update
Press releaseJun 26, 8:30 AM ETGlobe Newswire
NetworkNewsAudio Announces Audio Press Release (APR) the Advancement of First-in-Class Treatment for Multiple Sclerosis
Press releaseJun 25, 8:30 AM ETGlobe Newswire
Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy
Press releaseJun 24, 8:30 AM ETGlobe Newswire
The Quest to Repair What Multiple Sclerosis Takes Away
Press releaseJun 23, 8:30 AM ETGlobe Newswire
Quantum BioPharma Ltd. (NASDAQ: QNTM) Developing Patented, First-in-Class MS Treatment That Offers Different Approach
Press releaseJun 22, 8:30 AM ETGlobe Newswire
Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
Press releaseJun 2, 8:00 AM ETGlobe Newswire
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.
Press releaseJun 2, 7:40 AM ETGlobe Newswire
Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns
Press releaseJun 1, 7:30 PM ETGlobe Newswire
Quantum BioPharma Provides Corporate Update
NewsMay 28, 6:38 AM ETSnigdha Gairola
Quantum BioPharma Momentum Score Surges As Investors Cheer Progress In MS Research
NewsMay 26, 1:05 PM ET
12 Health Care Stocks Moving In Tuesday's Intraday Session
NewsMay 26, 8:06 AM ET
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Press releaseMay 18, 3:00 AM ETGlobe Newswire
Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital
NewsMar 30, 8:05 AM ET
12 Health Care Stocks Moving In Monday's Pre-Market Session
NewsMar 24, 1:05 PM ET
12 Health Care Stocks Moving In Tuesday's Intraday Session
NewsMar 12, 1:05 PM ET
12 Health Care Stocks Moving In Thursday's Intraday Session
NewsMar 11, 1:06 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
NewsNov 26, 12:05 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
NewsMay 6, 4:32 AM ET
Earnings Scheduled For May 6, 2025

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Top Wall Street Forecasters Revamp Thermo Fisher Scientific Expectations Ahead Of Q3 Earnings

World Renowned Law Firm Grant & Eisenhofer Appointed Lead Counsel In Newly Consolidated Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares

Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis

EXCLUSIVE: Thermo Fisher To Support Quantum Biopharma in Progressive Multiple Sclerosis Drug Trial

IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.

Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO

Quantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto

NetworkNewsAudio Announces Audio Press Release (APR) Discussing FDA Clearance for Trial of First-in-Class Treatment Creating ‘Rare Moment’ in MS Research

Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market

Quantum BioPharma Ltd. NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment

A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach

Reported Earlier, Quantum BioPharma Plans To Leave Canadian Exchange While Keeping Nasdaq Listing

Quantum BioPharma Announces Plans to Voluntarily Delist its Class B Shares from the Canadian Securities Exchange

Quantum Biopharma Provides Corporate Update

12 Health Care Stocks Moving In Monday's Pre-Market Session

Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial

Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis:

EXCLUSIVE: Quantum BioPharma Achieves Major Milestone With FDA Clearance for Multiple Sclerosis Trial

Quantum BioPharma Announces Closing of Debt Settlement

Quantum BioPharma Announces Intention to Settle Debt

Quantum BioPharma Provides Corporate Update

NetworkNewsAudio Announces Audio Press Release (APR) the Advancement of First-in-Class Treatment for Multiple Sclerosis

Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy

The Quest to Repair What Multiple Sclerosis Takes Away

Quantum BioPharma Ltd. (NASDAQ: QNTM) Developing Patented, First-in-Class MS Treatment That Offers Different Approach

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.

Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns

Quantum BioPharma Provides Corporate Update

Quantum BioPharma Momentum Score Surges As Investors Cheer Progress In MS Research

12 Health Care Stocks Moving In Tuesday's Intraday Session

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital

12 Health Care Stocks Moving In Monday's Pre-Market Session

12 Health Care Stocks Moving In Tuesday's Intraday Session

12 Health Care Stocks Moving In Thursday's Intraday Session

12 Health Care Stocks Moving In Wednesday's Intraday Session

12 Health Care Stocks Moving In Wednesday's Intraday Session

Earnings Scheduled For May 6, 2025